(CSL:Australian Stock Exchange Ltd)
John H. Akehurst MA (Oxon), FIMechE, FAICD
Non-Executive Director, Chairman of Human Resources & Remuneration Committee and Member of Nomination Committee, CSL Ltd.
|Age||Total Calculated Compensation||This person is connected to 39 board members in 8 different organizations across 10 different industries.|
See Board Relationships
Mr. John H. Akehurst, MA (Oxon), FIMechE, FAICD, served as the Managing Director and Chief Executive Officer of Woodside Petroleum Ltd. from 1996 to 2003. Mr. Akehurst has 30 years of experience in the international hydrocarbon industry. He held a number of engineering and management positions with the Royal Dutch/Shell Group of Companies from 1976 to 1996. He served as a Senior Adviser of McKinsey and Company. He serves as Chairman of The Fortitude Foundation and National ...
45 Poplar RoadPhone: 61 3 9389 1911
Parkville, Victoria 3052
Fax: 61 3 9389 1434
Board Members Memberships*
Former Managing Director and Director
Deputy Chairman, Chairman of Health, Safety & Environment Committee, Member of Oil & Gas Exploration Committee and Member of Risk & Audit Committee
Non-Executive Director, Chairman of Human Resources & Remuneration Committee and Member of Nomination Committee
Chairman, Chairman of Remuneration & Nomination Committee and Member of Independent Directors Committee
Independent Non Executive Director, Chairman of Health, Safety & Environment Committee, Member of Risk Committee and Member of Nomination Committee
Former Non-Executive Director
University of Oxford
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
|Robert L. Parkinson Jr.||Chairman, Chief Executive Officer and President|
Baxter International Inc.
|Flemming Ornskov M.D., MBA, MPH||Managing Director, Chief Executive Officer and Director|
|Victor Grifols Roura||Chairman, Chief Executive Officer, President and Member of Appointments & Remuneration Committee|
|Yoshihiko Hatanaka||Chief Executive Officer, President and Representative Director|
Astellas Pharma, Inc.
|¥170.0M||Compensation as of Fiscal Year 2014.|